arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Indaptus Therapeutics, Inc.

INDP

$4.03 ▲ +0.31 (+8.33%) at close

7 Visible periods

19 Metrics

Absolute Benchmarks

Price Chart

Health

Weak

Bearish Absolute basis

auto_awesome

Analytical Summary

On an absolute basis, Indaptus Therapeutics, Inc. shows weak fundamentals, weighed down by Return on Invested Capital and FCF / Net Income. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $3.9M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -629.4% ↘

FCF / Share $-15.34 ↗

Trailing P/E —

Price / Book 2.8x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Sep 24, 2026.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-20.85M

↓ -38.8% —

FCF / Share Free cash flow per share

$-15.34

↑ +58.4% —

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Invested CapitalReturn on Invested Capital of -629.4% is weak on an absolute basis (target > 10%)
FCF / Net IncomeFCF / Net Income of 0.71x is caution on an absolute basis (target > 1x)

Health Breakdown

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
EPS Growth YoY (%)	52.0% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-2356.8% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-5.8% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	8.5% Fair Fair Year-over-year change in earnings per share Optimal: > 10%	—	—	—
Net Income Growth YoY (%)	-38.8% Weak ↓ Weak Declining Year-over-year change in net income	2.6% Caution ↑ Caution Improving Year-over-year change in net income	-7.7% Weak ↑ Weak Improving Year-over-year change in net income	-85.7% Weak Weak Year-over-year change in net income	-115.2% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	58.4% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	-2211.3% Weak ↓ Weak Declining Year-over-year change in free cash flow	-0.8% Weak Weak Year-over-year change in free cash flow	42.7% Excellent Excellent Year-over-year change in free cash flow	—	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Effective Tax Rate (%) (%)	-0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—	—	—
FCF / Net Income (x)	0.71x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.82x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.87x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.91x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.46x Good Good Free cash flow relative to reported net income Optimal: > 1x	0.93x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Return on Invested Capital (%)	-629.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-389.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-107.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-47.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-17.0% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	1196.2% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-213.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-209.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-109.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-53.1% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-19.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	-202.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	—	—	-127.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-951%)	-58.2% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-488%)	-21.5% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-243%)	—	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Net Debt (USD)	$-8.51M	$-5.79M	$-13.36M	$-9.63M	$-39.13M	$-1.64M	—

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Basic EPS, GAAP (USD)	$-21.58	$-44.96	$-1.83	$-1.73	$-1.89	—	—
Free Cash Flow per Share (USD)	$-15.34	$-36.88	$-1.60	$-1.58	$-2.76	—	—
Book Value per Share (USD)	$1.45	$9.20	$1.44	$2.93	$4.35	$-0.12	—
Tangible Book Value per Share (USD)	$1.45	$9.20	$1.44	$2.93	$4.35	$-0.12	—
Basic Weighted Avg Shares (shares)	966,124	334,133	8.40M	8.26M	4.09M	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Working Capital (USD)	$3.15M	$3.22M	$11.22M	$23.81M	$35.78M	$-283.50K	—
Total Equity (USD)	$3.15M	$3.94M	$12.08M	$24.63M	$35.90M	$-237.70K	$3.21M

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Depreciation Expense (USD)	—	$735.00	$1.28K	$1.78K	$1.40K	$852.00	—
Net Income, GAAP (USD)	$-20.85M	$-15.02M	$-15.42M	$-14.32M	$-7.71M	$-3.58M	—
Operating Cash Flow (USD)	$-14.82M	$-12.32M	$-13.41M	$-13.08M	$-11.29M	$-3.32M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 2 days ago 7 years · 27 quarters

Indaptus Therapeutics, Inc.

Analytical Summary

7-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Benchmarks unavailable

Compare INDP with peers